Labgenomics Co

Labgenomics Co Equity Turnover

The Equity Turnover of Labgenomics Co (084650.KQ) as of Oct 26, 2026 is 0.59. In the previous year, Equity Turnover was 0.40 — a change of 48.38% (higher).

Equity Turnover

0.59

YoY

48.38%

Last updated:

Equity Turnover of Labgenomics Co is 2025 0.59 . Equity Turnover of Labgenomics Co was 2024 0.40 . It decreases by 48.38% higher compared to the previous year.

The Labgenomics Co Equity Turnover history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Turnover
Date
Equity Turnover
Jan 1, 2018
0.91 KRW
Jan 1, 2019
1.09 KRW
Jan 1, 2020
1.47 KRW
Jan 1, 2021
1.28 KRW
Jan 1, 2022
0.69 KRW
Jan 1, 2023
0.31 KRW
Jan 1, 2024
0.40 KRW
Jan 1, 2025
0.59 KRW
The Labgenomics Co Equity Turnover history
YEAREquity TurnoverYoY
0.59+48.38%
0.40+27.27%
0.31-54.88%
0.69-46.11%
1.28-12.41%
1.47+34.34%
1.09+19.22%
0.91-17.58%
1.11+15.53%
0.96-9.78%
1.06-2.52%
1.09—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Labgenomics Co Stock analysis

What does Labgenomics Co do? LabGenomics Co., Ltd. generates revenue through the provision of in vitro diagnostic (IVD) products and services. The company offers general diagnostic check services, molecular diagnostic check services, and research and development services, alongside IVD products such as DNA chips and PCR kits. Its diagnostic services include examinations for breast cancer and colorectal cancer, while its biosensor solutions target point of care testing (POCT). Additionally, LabGenomics sells healthy food as part of its product portfolio. The primary buyers of LabGenomics' services are healthcare institutions requiring diagnostic support, including hospitals and clinics. The company's molecular diagnostic services and cancer examinations are particularly sought after by medical facilities focused on specialized testing. Healthcare providers also purchase its biosensor solutions for immediate testing at the point of care. LabGenomics' product segments include IVD services, IVD products like DNA chips and PCR kits, cancer examination services, and healthy food. The company's molecular diagnostic services and cancer testing are key revenue drivers, while its biosensor for POCT and healthy food offerings serve complementary market segments. Labgenomics Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Labgenomics Co stock

Equity Turnover of Labgenomics Co is 0.59 in 2025.

Equity Turnover of Labgenomics Co changed from 0.40 to 0.59, representing a 48.38% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Equity Turnover Labgenomics Co since 2006 – with annual values, charts, and detailed analysis.

Equity turnover measures how efficiently a company uses shareholders' equity to generate revenue. It is a component of the DuPont analysis framework.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Turnover's Labgenomics Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Equity Turnover's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Equity Turnover.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Labgenomics Co

All Key Metrics — Labgenomics Co